Abbott Depakote ER epilepsy indication
This article was originally published in Pharmaceutical Approvals Monthly
Abbott's Depakote ER (divalproex sodium extended-release) is approved Dec. 20 as once-daily monotherapy and adjunctive therapy for complex partial seizures in epileptic adults. Approval was based on two trials comparing once-daily Depakote ER to twice-daily and three times daily dosing of immediate-release Depakote
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.